- Home
- MYX vs FATE Comparison
MYX vs FATE Comparison
Compare MYX & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MYX | FATE |
|---|---|---|
| Founded | 2025 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 146.0M | 125.6M |
| IPO Year | 2025 | 2013 |
Fundamental Metrics
Financial Performance| Metric | MYX | FATE |
|---|---|---|
| Price | $10.03 | $2.19 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $5.74 |
| AVG Volume (30 Days) | 5.0K | ★ 1.6M |
| Earning Date | N/A | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.88 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,646,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.88 | $0.95 |
| 52 Week High | $10.05 | $3.23 |
Technical Indicators
Market Signals| Indicator | MYX | FATE |
|---|---|---|
| Relative Strength Index (RSI) | 69.66 | 39.15 |
| Support Level | $9.89 | $1.06 |
| Resistance Level | $10.05 | $2.62 |
| Average True Range (ATR) | 0.01 | 0.15 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 84.68 | 25.83 |
Price Performance
Historical ComparisonAbout MYX Maywood Acquisition Corp. 2 Class A Ordinary Share
Maywood Acquisition Corp 2 is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities.
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.